2025

NervGen Pharma Announces Filing of Form F-10 Registration Statement with the SEC under MJDS

NervGen Pharma Announces Proposed Amendment to Warrants

NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates

NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury

NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development

NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development

NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders

NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury

NervGen Announces Leadership Transition to Support Strategic Growth and Expansion